Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
Identifieur interne : 000050 ( Hal/Curation ); précédent : 000049; suivant : 000051Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
Auteurs : David Devos [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-05-15.
Abstract
The studies of duodenal infusion of a levodopa on small groups of parkinsonian patients have reported beneficial effects on motor complications. However, little is known about the patient profile and indications for duodenal levodopa infusion. The purpose of this study is to exhaustively investigate the clinical characteristics of the population and indication, efficacy and tolerability of duodenal levodopa infusion in natural care settings. Of the 102 patients treated with duodenal levodopa infusion since 2003, 91 were enrolled in a multicentre retrospective study. The mean age was 72.7 years, with average disease duration of 17 years. Patients were at advanced stage: 91% had gait disorders, 65% had visual hallucinations, and 50% were demented (MMSE: 23). Duodenal levodopa infusion was the last line of treatment for motor complications in 98% of the patients, due to failure of or contraindication for apomorphine pump and neurosurgical treatments. Long-term treatment was observed by 73% of the population. Of these, >90% reported an improvement in motor fluctuations, quality of life, and autonomy. There were few severe adverse events. Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last-line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered.
Url:
DOI: 10.1002/mds.22450
Links toward previous steps (curation, corpus...)
- to stream Hal, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000050
Links to Exploration step
Hal:inserm-00410554Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-99761" status="INCOMING"><orgName>Department of Neurology et Pathologie du Mouvement</orgName><orgName type="acronym">IMRT, EA2683</orgName><desc><address><addrLine>Hôpital R. Salengro, Clinique Neurologique, Lille</addrLine><country key="FR"></country></address></desc><listRelation><relation active="#struct-300070" type="direct"></relation><relation active="#struct-306165" type="direct"></relation></listRelation><tutelles><tutelle active="#struct-300070" type="direct"><org type="institution" xml:id="struct-300070" status="VALID"><orgName>CHRU Lille</orgName><desc><address><country key="FR"></country></address></desc></org></tutelle><tutelle active="#struct-306165" type="direct"><org type="institution" xml:id="struct-306165" status="INCOMING"><orgName>IFR114</orgName><desc><address><country key="FR"></country></address></desc></org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:inserm-00410554</idno><idno type="halId">inserm-00410554</idno><idno type="halUri">http://www.hal.inserm.fr/inserm-00410554</idno><idno type="url">http://www.hal.inserm.fr/inserm-00410554</idno><idno type="doi">10.1002/mds.22450</idno><date when="2009-05-15">2009-05-15</date><idno type="wicri:Area/Hal/Corpus">000050</idno><idno type="wicri:Area/Hal/Curation">000050</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-99761" status="INCOMING"><orgName>Department of Neurology et Pathologie du Mouvement</orgName><orgName type="acronym">IMRT, EA2683</orgName><desc><address><addrLine>Hôpital R. Salengro, Clinique Neurologique, Lille</addrLine><country key="FR"></country></address></desc><listRelation><relation active="#struct-300070" type="direct"></relation><relation active="#struct-306165" type="direct"></relation></listRelation><tutelles><tutelle active="#struct-300070" type="direct"><org type="institution" xml:id="struct-300070" status="VALID"><orgName>CHRU Lille</orgName><desc><address><country key="FR"></country></address></desc></org></tutelle><tutelle active="#struct-306165" type="direct"><org type="institution" xml:id="struct-306165" status="INCOMING"><orgName>IFR114</orgName><desc><address><country key="FR"></country></address></desc></org></tutelle></tutelles></hal:affiliation><country>France</country></affiliation></author></analytic><idno type="DOI">10.1002/mds.22450</idno><series><title level="j">Movement Disorders</title><idno type="ISSN">0885-3185</idno><imprint><date type="datePub">2009-05-15</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The studies of duodenal infusion of a levodopa on small groups of parkinsonian patients have reported beneficial effects on motor complications. However, little is known about the patient profile and indications for duodenal levodopa infusion. The purpose of this study is to exhaustively investigate the clinical characteristics of the population and indication, efficacy and tolerability of duodenal levodopa infusion in natural care settings. Of the 102 patients treated with duodenal levodopa infusion since 2003, 91 were enrolled in a multicentre retrospective study. The mean age was 72.7 years, with average disease duration of 17 years. Patients were at advanced stage: 91% had gait disorders, 65% had visual hallucinations, and 50% were demented (MMSE: 23). Duodenal levodopa infusion was the last line of treatment for motor complications in 98% of the patients, due to failure of or contraindication for apomorphine pump and neurosurgical treatments. Long-term treatment was observed by 73% of the population. Of these, >90% reported an improvement in motor fluctuations, quality of life, and autonomy. There were few severe adverse events. Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last-line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered.</div></front></TEI><hal api="V3"><titleStmt><title xml:lang="en">Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.</title><author role="crp"><persName><forename type="first">David</forename><surname>Devos</surname></persName><email>d-devos@chru-lille.fr</email><idno type="halauthor">427542</idno><affiliation ref="#struct-99761"></affiliation></author><editor role="depositor"><persName><forename>Marie Francoise</forename><surname>Simon</surname></persName><email>jerome.daguzan@inserm.fr</email></editor></titleStmt><editionStmt><edition n="v1" type="current"><date type="whenSubmitted">2009-08-21 13:11:30</date><date type="whenModified">2009-08-21 16:49:06</date><date type="whenReleased">2009-08-21 16:49:06</date><date type="whenProduced">2009-05-15</date></edition><respStmt><resp>contributor</resp><name key="118088"><persName><forename>Marie Francoise</forename><surname>Simon</surname></persName><email>jerome.daguzan@inserm.fr</email></name></respStmt></editionStmt><publicationStmt><distributor>CCSD</distributor><idno type="halId">inserm-00410554</idno><idno type="halUri">http://www.hal.inserm.fr/inserm-00410554</idno><idno type="halBibtex">devos:inserm-00410554</idno><idno type="halRefHtml">Movement Disorders, Wiley, 2009, 24 (7), pp.993-1000. <10.1002/mds.22450></idno><idno type="halRef">Movement Disorders, Wiley, 2009, 24 (7), pp.993-1000. <10.1002/mds.22450></idno></publicationStmt><seriesStmt><idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno></seriesStmt><notesStmt><note type="audience" n="2">International</note><note type="popular" n="0">No</note><note type="peer" n="1">Yes</note></notesStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.</title><author role="crp"><persName><forename type="first">David</forename><surname>Devos</surname></persName><email>d-devos@chru-lille.fr</email><idno type="halAuthorId">427542</idno><affiliation ref="#struct-99761"></affiliation></author></analytic><monogr><idno type="halJournalId" status="VALID">17211</idno><idno type="issn">0885-3185</idno><idno type="eissn">1531-8257</idno><title level="j">Movement Disorders</title><imprint><publisher>Wiley</publisher><biblScope unit="volume">24</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="pp">993-1000</biblScope><date type="datePub">2009-05-15</date></imprint></monogr><idno type="doi">10.1002/mds.22450</idno><idno type="pubmed">19253412</idno></biblStruct></sourceDesc><profileDesc><langUsage><language ident="en">English</language></langUsage><textClass><classCode scheme="mesh">Aged</classCode><classCode scheme="mesh">Antiparkinson Agents</classCode><classCode scheme="mesh">Parkinson Disease</classCode><classCode scheme="mesh">Personal Autonomy</classCode><classCode scheme="mesh">Quality of Life</classCode><classCode scheme="mesh">Retrospective Studies</classCode><classCode scheme="mesh">Treatment Outcome</classCode><classCode scheme="mesh">Dementia</classCode><classCode scheme="mesh">Duodenum</classCode><classCode scheme="mesh">Female</classCode><classCode scheme="mesh">Gait Disorders, Neurologic</classCode><classCode scheme="mesh">Hallucinations</classCode><classCode scheme="mesh">Humans</classCode><classCode scheme="mesh">Levodopa</classCode><classCode scheme="mesh">Male</classCode><classCode scheme="halTypology" n="ART">Journal articles</classCode></textClass><abstract xml:lang="en">The studies of duodenal infusion of a levodopa on small groups of parkinsonian patients have reported beneficial effects on motor complications. However, little is known about the patient profile and indications for duodenal levodopa infusion. The purpose of this study is to exhaustively investigate the clinical characteristics of the population and indication, efficacy and tolerability of duodenal levodopa infusion in natural care settings. Of the 102 patients treated with duodenal levodopa infusion since 2003, 91 were enrolled in a multicentre retrospective study. The mean age was 72.7 years, with average disease duration of 17 years. Patients were at advanced stage: 91% had gait disorders, 65% had visual hallucinations, and 50% were demented (MMSE: 23). Duodenal levodopa infusion was the last line of treatment for motor complications in 98% of the patients, due to failure of or contraindication for apomorphine pump and neurosurgical treatments. Long-term treatment was observed by 73% of the population. Of these, >90% reported an improvement in motor fluctuations, quality of life, and autonomy. There were few severe adverse events. Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last-line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered.</abstract><particDesc><org type="consortium">French DUODOPA Study Group</org></particDesc></profileDesc></hal></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Hal/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000050 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Curation/biblio.hfd -nk 000050 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Hal
|étape= Curation
|type= RBID
|clé= Hal:inserm-00410554
|texte= Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
}}
| This area was generated with Dilib version V0.6.23. |  |